Skip to main content

Drug Interactions between cabotegravir and Mycobutin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

rifabutin cabotegravir

Applies to: Mycobutin (rifabutin) and cabotegravir

CONTRAINDICATED: Coadministration with rifabutin may decrease the plasma concentrations of cabotegravir. The mechanism of interaction has not been established. In 12 study subjects given cabotegravir 30 mg once daily with rifabutin 300 mg once daily, mean cabotegravir peak plasma concentration (Cmax) and systemic exposure (AUC) were reduced by 17% and 21%, respectively.

MANAGEMENT: If cabotegravir is prescribed in combination with rilpivirine, concomitant use of rifabutin is considered contraindicated by the manufacturer.

References (3)
  1. Cerner Multum, Inc. (2015) "Canadian Product Information."
  2. (2021) "Product Information. Cabenuva (cabotegravir-rilpivirine)." ViiV Healthcare ULC
  3. (2021) "Product Information. Vocabria (cabotegravir)." ViiV Healthcare

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer